Previous Article | Next Article ![]()
Journal of Clinical Microbiology, June 1998, p. 1584-1587, Vol. 36, No. 6
Instituto de Microbiologia, Universidade
Federal do Rio de Janeiro, Rio de Janeiro 21941, Brazil,1 and
Division of Bacterial and
Mycotic Diseases, National Center for Infectious Diseases, Centers
for Disease Control and Prevention, Atlanta, Georgia
303332
Received 10 November 1997/Returned for modification 20 January
1998/Accepted 24 February 1998
A total of 107 Enterococcus strains, 10 Vagococcus fluvialis strains, and 8 Lactococcus
garvieae strains were tested for acidification of
methyl-
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Use of Tests for Acidification of
Methyl-
-D-Glucopyranoside and Susceptibility to
Efrotomycin for Differentiation of Strains of
Enterococcus and Some Related Genera
-D-glucopyranoside (MGP) and susceptibility to
100-µg efrotomycin (EFRO) disks. All 26 strains of
Enterococcus casseliflavus, including 3 nonmotile and 2 nonpigmented strains, acidified MGP and were resistant to EFRO. All 22 strains of Enterococcus gallinarum, including 5 nonmotile
strains, also acidified MGP and were resistant to EFRO. None of the 26 strains of Enterococcus faecium acidified MGP, and all were
susceptible to EFRO. Although all 12 Enterococcus faecalis
strains were also negative in the MGP test, they were resistant to
EFRO. Other enterococcal strains gave variable results. All 10 strains
of V. fluvialis and all 8 strains of L. garvieae gave positive and negative results, respectively, in the
MGP test and were, respectively, resistant and susceptible to
EFRO. These results indicate that tests of the production of acid from
MGP and susceptibility to EFRO can be used as adjunct tests in the identification of typical and atypical strains of enterococci in the
clinical microbiology laboratory.
*
Corresponding author. Mailing address: Childhood and
Respiratory Diseases Branch MS-C02, Centers for Disease Control and
Prevention, Atlanta, GA 30333. Phone: (404) 639-1379. Fax: (404)
639-3123. E-mail: rrf2{at}cdc.gov.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|